Home > Press > Alltracel Pharmaceuticals Plc ("Alltracel" or the "Company") Directors' Shareholding
Alltracel CEO Tony Richardson Increases Shareholding
Alltracel Pharmaceuticals Plc ("Alltracel" or the "Company") Directors' Shareholding
DUBLIN and LONDON | Posted on April 17th, 2007
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"),(LSE: AP) (AIM:AP.L),
the Healthcare Innovation Group focused on the Wound Care, Oral Care and
Cardiovascular Health markets was informed today that Tony Richardson,
Chief Executive Officer of the Company, acquired 150,000 ordinary shares of
EUR0.0125 each ("Ordinary Shares") on 17 April 2007. The Ordinary Shares
were bought at GBP0.12 p each and following this acquisition, Mr Richardson
now holds a total of 1,885,306 Ordinary Shares, which represents
approximately 1.36 per cent of the Company's issued share capital.
About Alltracel Pharmaceuticals Plc
Alltracel, (AIM: AP.L) (http://www.alltracel.com) the Healthcare Innovation
group is focused on taking proprietary technology from research right
through to commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and
is a public company which listed on London's Alternative Investment Market
in July 2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a
commercial office in London, England; R&D subsidiary in the Czech Republic
and manufacturing facilities in Shenzhen, China. Alltracel also has a wide
network of research, development and manufacturing partners in Europe, Asia
and North America.
Alltracel operates via two main divisions Alltracel Healthcare Group
and Alltracel Healthcare Technologies:
Alltracel Healthcare Technologies is focused on the commercialisation
effort behind proven innovation technologies and services for the global
healthcare market. Alltracel Healthcare Group has a range of stake
holdings, joint ventures and wholly owned business units operating in a
variety of healthcare categories including Wound Care, Oral Care,
- Alltracel's specialist Oral Care subsidiary Westone (http://www.westone.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM)
(http://www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and
is dedicated to the commercialisation of Nanospider(TM) technology for the
global healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by
For more information, please click here
For Further Information Contact:
Dublin: Denise Cronin Alltracel: +353-1-235-2162
London: Deborah Scott Financial Dynamics: +44-(0)207-831-3113
New York: Sean Leous Financial Dynamics: +1-212-850-5626
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Notes ABSMaterials' Series B Financing November 22nd, 2013
Harris & Harris Group Letter to Shareholders on Website November 18th, 2013
Harris & Harris Group Reports Financial Statements as of September 30, 2013 November 12th, 2013
Harris & Harris Group Notes CordenPharma's Acquisition of Ancora's Carbohydrate Synthesis Platform and Corporate Name November 7th, 2013
Synthesis of superconducting picene crystals December 12th, 2013
Iranian Scientists Discover New Electrical Device for Rapid Diagnosis of Cancer December 12th, 2013
3-D Analysis of Thermo-elastic Behavior of Composite Plate Graded with Carbon Nanotubes December 12th, 2013
Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results - Conference Call Scheduled for Wednesday, December 18, 2013 December 12th, 2013